Seoul Economic Daily EnglishDoubao · 实盘不做把握 6/10不做原因:无可交易标的
北京时间·🕒 发布 13:36:43(首尔 14:36)·⟳ 抓取 13:55:00 +18m17s·⚡ 决策 10-27 18:47:34 +4h52m·7.1 小时前
ST Pharm三季度营收增19.1%但净利润暴跌94.8%，寡核苷酸订单强劲与汇率拖累并存
直接主体ST Pharm仅在韩国KOSDAQ上市(237690.KQ)，本环境无韩股行情源，无法核验14:36财报发布后的真实价格反应与执行条件；同时财报为典型多空交织(收入/订单强 vs 净利润-94.8%、利润率收窄)，事件方向MIXED；向A股寡核苷酸/多肽CDMO的映射缺乏共同需求催化，属弱二阶联想，不构成正期望交易。
📄 原文Seoul Economic Daily English↗ 原文
ST Pharm Q3 Revenue Rises 19.1% on Oligo Orders
ST Pharm (237690.KQ) posted higher revenue and operating profit in the third quarter, driven by a rise in commercial or…
不做 ST Pharm（237690.KQ）
不可执行+方向不明：直接标的为KOSDAQ股票，本环境无韩股行情与下单覆盖，无法核验财报发布后(14:36-15:30)的真实定价及次日开盘条件；财报MIXED(寡核苷酸收入+45.6%/在手订单2.7亿美元 vs 净利润-94.8%、营业利润率降至16.1%)，无清晰正期望方向；A股CDMO映射无共同订单或需求催化，不另开联动腿。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
ST Pharm三季报核心寡核苷酸业务强劲(收入+45.6%、在手订单2.7亿美元)，但净利润受汇兑损失拖累暴跌94.8%、营业利润率收窄，多空交织方向不明；且唯一直接标的为无行情覆盖的KOSDAQ股票，跨市场映射无因果支撑，故不做。
🔎 新鲜度:最早出现 2026-10-27 · 扩散 low · price-in 风险 medium ↗
关键理由
- 经营性数据实际偏正面：营业利润仍同比+6.6%，净利润暴跌主要来自韩元升值的非经营性汇兑损失，而非核心需求恶化。
- 但本环境无法交易/定价237690.KQ，财报发布时距KOSDAQ收盘不足1小时，无法确认市场选择定价"订单强"还是"净利润崩"。
主要风险
- 若市场只交易净利润-94.8%的标题，次日可能低开；反之若聚焦2.7亿美元在手订单与78%商业化占比，可能高开，方向在无行情核验下不可判。
- 韩元若继续走强，四季度汇兑损失与外币收入折算压力可能延续，订单强劲无法直接转化为利润弹性。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-27 · 影响 weakens
正文本身即含强反证：净利润同比-94.8%、营业利润率18%→16.1%、子公司收入-5.6%，低毛利仿制药占比上升；多空因素同文并存，无法确立单一做多方向。
检索:ST Pharm Q3 net profit FX loss margin decline 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例缺失强化了低置信度与不做决定，但决定性因素仍是无可交易/定价载体与MIXED方向。
方向:无可权衡先例；韩国中小盘CDMO"营收/订单强+汇兑致净利润崩"的财报在本环境无对齐样本。
涨幅量级:无法校准幅度，且直接标的无行情、不可执行，先例幅度不改变结论。
形态:未检索；多空交织财报次日方向取决于市场焦点，无可靠模式。
工具执行结果 · 成功 1 · 降级 1 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 332 ms
{"result": "search_processed_events:agent query=`st pharm 237690 q3 earnings oligonucleotide revenue | st pharm 3분기 실적 올리고뉴클레오타이드 수주 | st pharm oligonucleotide backlog 270 million net profit`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 68.5/72 小时、4075 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按 - stock_quote 降级 stock_tools HTTP · 8 ms
本机没有该市场的行情源(数据中台只覆盖美股、港股、A股)。不能用本工具核验价格和可执行条件；如需交易请改选美/港/A股上的可交易载体，否则在 reason 里注明无法定价，不得编造价位。
原文全文
展开原文 · 2,195 字
ST Pharm (237690.KQ) posted higher revenue and operating profit in the third quarter, driven by a rise in commercial orders for oligonucleotides, the key raw material in RNA-based therapeutics. Its operating margin narrowed, however, as lower-margin products such as generic drugs accounted for a larger share of sales, and net profit declined as the won strengthened against the dollar.
ST Pharm said on the 27th that third-quarter revenue reached 97.6 billion won and operating profit 15.7 billion won. Revenue rose 19.1% and operating profit 6.6% from a year earlier. Sales of commercial oligonucleotide products climbed 45.6% to 49.7 billion won from 34.1 billion won a year earlier.
New oligonucleotide orders are also expanding. The company won 12 new orders this year, adding four in the third quarter after eight in the first half. Indications are broadening to include obesity, neurological disorders, metabolic diseases and autoimmune diseases. As of the end of September, the oligonucleotide order backlog stood at about $270 million, with commercial projects accounting for roughly 78% of the total.
Revenue from small-molecule drugs grew sharply to 11.6 billion won from 100 million won a year earlier. "Small-molecule drugs are also growing on higher revenue from commercial projects, and we expect that growth to continue," a company official said, adding that the order backlog stood at about $40 million as of the end of September.
Despite the gains in revenue and operating profit, the operating margin fell to 16.1% from 18% a year earlier. Generic drug sales, which carry relatively low margins, rose to 7.7 billion won in the third quarter from 2.5 billion won a year earlier, and the stronger won also weighed on profitability. Net profit fell 94.8% from a year earlier to 900 million won, as foreign exchange losses and currency translation losses tied to the stronger won cut into earnings.
In messenger RNA, including personalized cancer vaccines, the company secured two new orders and booked about 500 million won in revenue. Revenue from subsidiaries running businesses such as contract research organization services fell 5.6% from a year earlier to 8.8 billion won.
ST Pharm said on the 27th that third-quarter revenue reached 97.6 billion won and operating profit 15.7 billion won. Revenue rose 19.1% and operating profit 6.6% from a year earlier. Sales of commercial oligonucleotide products climbed 45.6% to 49.7 billion won from 34.1 billion won a year earlier.
New oligonucleotide orders are also expanding. The company won 12 new orders this year, adding four in the third quarter after eight in the first half. Indications are broadening to include obesity, neurological disorders, metabolic diseases and autoimmune diseases. As of the end of September, the oligonucleotide order backlog stood at about $270 million, with commercial projects accounting for roughly 78% of the total.
Revenue from small-molecule drugs grew sharply to 11.6 billion won from 100 million won a year earlier. "Small-molecule drugs are also growing on higher revenue from commercial projects, and we expect that growth to continue," a company official said, adding that the order backlog stood at about $40 million as of the end of September.
Despite the gains in revenue and operating profit, the operating margin fell to 16.1% from 18% a year earlier. Generic drug sales, which carry relatively low margins, rose to 7.7 billion won in the third quarter from 2.5 billion won a year earlier, and the stronger won also weighed on profitability. Net profit fell 94.8% from a year earlier to 900 million won, as foreign exchange losses and currency translation losses tied to the stronger won cut into earnings.
In messenger RNA, including personalized cancer vaccines, the company secured two new orders and booked about 500 million won in revenue. Revenue from subsidiaries running businesses such as contract research organization services fell 5.6% from a year earlier to 8.8 billion won.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
1a519fbd03· 2026-10-27 18:47 · doubao / doubao-seed-evolving-latest-version · 策略包b7b4acf827b8当前